Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Autor: Thozhukat Sathyapalan, Andrei-Mircea Catarig, Patrick Holmes, Jean-François Yale, Ulrik Bodholdt, Sergiu Catrina, Alice Clark, Neda Rajamand Ekberg, Umut Erhan, Søren Tang Knudsen, Joanne Liutkus, Bernd Schultes, Gottfried Rudofsky

Publikováno v: BMJ Open Diabetes Research & Care, Vol 10, Iss 2 (2022)

Externí odkaz: https://doaj.org/article/c62708ce246d49819106d68b235a3c72

Author response for 'Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes'

Autor: null Vanita R. Aroda, null Umut Erhan, null Peter Jelnes, null Juris J. Meier, null Morten Tind Abildlund, null Richard Pratley, null Tina Vilsbøll, null Mansoor Husain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::64b6fc1340e0eb37f665aa3d0fe912ff
https://doi.org/10.1111/dom.14990/v2/response1

Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies

Autor: Jean-François Yale, Andrei-Mircea Catarig, Sergiu-Bogdan Catrina, Umut Erhan, Thozhukat Sathyapalan, Bernd Schultes, Ines Witte, Mohd Tariq, Søren Tang Knudsen

Publikováno v: Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0c103b9e9c3b18ca13d647d1dd312e6
https://doi.org/10.1055/s-0042-1746335

645-P: Mobile Health Application as a Real-World Data Resource: Self-Recorded Weight Reduction with Once-Weekly Semaglutide

Autor: Umut Erhan, Sophie Birot, Andrei-Mircea Catarig, Ulrik Bodholdt, Filip K. Knop

Publikováno v: Diabetes. 70

A mobile health application (mHealth app) with treatment planning, body weight and dose tracking features has been developed to support patients with type 2 diabetes (T2D) initiating once-weekly (OW) semaglutide, a glucagon-like peptide-1 analog. Her

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce867cff53932a7f126d260e86825349
https://doi.org/10.2337/db21-645-p

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Autor: Jean-François Yale, Ulrik Bodholdt, Andrei-Mircea Catarig, Sergiu Catrina, Alice Clark, Neda Rajamand Ekberg, Umut Erhan, Patrick Holmes, Søren Tang Knudsen, Joanne Liutkus, Thozhukat Sathyapalan, Bernd Schultes, Gottfried Rudofsky

Publikováno v: Yale, J F, Bodholdt, U, Catarig, A M, Catrina, S, Clark, A, Ekberg, N R, Erhan, U, Holmes, P, Knudsen, S T, Liutkus, J, Sathyapalan, T, Schultes, B & Rudofsky, G 2022, ' Real-world use of once-weekly semaglutide in patients with type 2 diabetes : Pooled analysis of data from four SURE studies by baseline characteristic subgroups ', BMJ Open Diabetes Research and Care, vol. 10, no. 2, e002619 . https://doi.org/10.1136/bmjdrc-2021-002619

IntroductionThis post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4416e9a70fc551fba064bcfa935f6206
https://doi.org/10.1136/bmjdrc-2021-002619